Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2020-07-02 | WVE | Wave Life Sciences Ltd. | Bolno Paul | Pres, CEO | S - Sale+OE | $10.30 | -147,577 | 272,181 | -35% | -$1,520,276 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | 5Am Ventures V, L.P. | 10% | P - Purchase | $17.00 | +294,117 | 1,094,101 | +37% | +$4,999,989 | |||||
| D | 2020-07-01 | PRNB | Principia Biopharma Inc. | Colowick Alan | Dir | S - Sale+OE | $60.00 | -7,500 | 0 | -100% | -$450,000 | |||||
2020-07-01 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $22.27 | -500 | 76,493 | -1% | -$11,136 | ||||||
| D | 2020-07-01 | ZTS | Zoetis Inc. | Trawicki Roman | EVP | S - Sale+OE | $137.29 | -5,499 | 1,421 | -79% | -$754,958 | |||||
| D | 2020-07-01 | ZTS | Zoetis Inc. | Chen Heidi C. | EVP | S - Sale+OE | $137.29 | -1,179 | 16,335 | -7% | -$161,865 | |||||
| D | 2020-07-01 | STOK | Stoke Therapeutics, Inc. | Nash Huw M. | COO, CBO | S - Sale+OE | $23.15 | -3,800 | 0 | -100% | -$87,968 | |||||
2020-07-01 | APLS | Apellis Pharmaceuticals, Inc. | Grossi Federico | See Remarks | S - Sale | $32.43 | -850 | 30,125 | -3% | -$27,566 | ||||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Ecor1 Capital, LLC | 10% | P - Purchase | $17.00 | +1,176,000 | 1,975,984 | +147% | +$19,992,000 | |||||
2020-07-01 | FREQ | Frequency Therapeutics, Inc. | Lucchino David L. | Pres, CEO | S - Sale | $22.45 | -15,714 | 402,372 | -4% | -$352,833 | ||||||
| D | 2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | Johnson & Johnson | 10% | P - Purchase | $17.00 | +725,000 | 3,670,516 | +25% | +$12,325,000 | |||||
| DM | 2020-07-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $121.06 | -20,000 | 664,185 | -3% | -$2,421,134 | |||||
2020-07-01 | TCDA | Tricida, Inc. | Klaerner Gerrit | Pres, CEO | S - Sale | $27.15 | -4,000 | 576,644 | -1% | -$108,600 | ||||||
| M | 2020-06-30 | RYTM | Rhythm Pharmaceuticals, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $22.06 | -131,581 | 5,140,408 | -2% | -$2,902,517 | |||||
2020-07-01 | HZNP | Horizon Therapeutics Public Ltd Co | Moze Barry | EVP, Chief Admin. Officer | S - Sale | $54.64 | -23,158 | 143,133 | -14% | -$1,265,441 | ||||||
2020-07-01 | CARA | Cara Therapeutics, Inc. | Chalmers Derek T | Pres, CEO | S - Sale | $17.11 | -5,000 | 961,421 | -1% | -$85,550 | ||||||
2020-07-01 | NGM | Ngm Biopharmaceuticals Inc | Chen Jin-Long | Chief Scientific Officer | S - Sale | $18.91 | -25,000 | 1,020,005 | -2% | -$472,728 | ||||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $17.00 | +825,000 | 2,281,249 | +57% | +$14,025,000 | |||||
| D | 2020-06-30 | BBIO | Bridgebio Pharma, Inc. | Turtle Cameron | See Remarks | S - Sale+OE | $32.66 | -10,000 | 9,823 | -50% | -$326,623 | |||||
2020-07-01 | FULC | Fulcrum Therapeutics, Inc. | Cadavid Diego | SVP Clinical Development | S - Sale | $18.30 | -1,071 | 65,714 | -2% | -$19,599 | ||||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Parmar Kush | Dir, 10% | P - Purchase | $17.00 | +294,117 | 1,094,101 | +37% | +$4,999,989 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Preston Heather | Dir | P - Purchase | $17.00 | +299,999 | 1,799,970 | +20% | +$5,099,983 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Novartis Bioventures Ltd | Former 10% Owner | P - Purchase | $17.00 | +125,000 | 1,181,258 | +12% | +$2,125,000 | |||||
| D | 2020-07-01 | STSA | Satsuma Pharmaceuticals, Inc. | O'Neil Thomas P. | CFO | S - Sale+OE | $26.65 | -1,000 | 0 | -100% | -$26,654 | |||||
2020-06-30 | VRTX | Vertex Pharmaceuticals Inc / Ma | Leiden Jeffrey M | Exec COB | S - Sale | $286.15 | -32,792 | 2,701 | -92% | -$9,383,304 | ||||||
| D | 2020-07-01 | STSA | Satsuma Pharmaceuticals, Inc. | Albrecht Detlef | Chief Medical Officer | S - Sale+OE | $26.68 | -1,000 | 20,212 | -5% | -$26,683 | |||||
2020-07-01 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Beetham Thomas W. | EVP, GC | S - Sale | $25.37 | -29,589 | 0 | -100% | -$750,678 | ||||||
| D | 2020-07-01 | KRTX | Karuna Therapeutics, Inc. | Brannan Stephen K. | Chief Medical Officer | S - Sale+OE | $108.53 | -7,728 | 15,000 | -34% | -$838,720 | |||||
| D | 2020-07-01 | REGN | Regeneron Pharmaceuticals, Inc. | Brown Michael S | Dir | S - Sale+OE | $607.62 | -3,613 | 16,992 | -18% | -$2,195,342 | |||||
2020-07-01 | REGN | Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Dir | S - Sale | $609.70 | -100 | 28,643 | 0% | -$60,970 | ||||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Cormorant Asset Management, LP | Former 10% Owner | P - Purchase | $17.00 | +290,000 | 789,989 | +58% | +$4,930,000 | |||||
2020-06-30 | HGEN | Humanigen, Inc | Nomis Bay Ltd. | 10% | S - Sale | $4.91 | -3,000 | 32,989,270 | 0% | -$14,739 | ||||||
2020-06-30 | RMTI | Rockwell Medical, Inc. | Richmond David S. | See Footnotes 1 and 2, 10% | P - Purchase | $1.93 | +24,681 | 6,315,587 | 0% | +$47,563 | ||||||
2019-07-29 | RMTI | Rockwell Medical, Inc. | Richmond Brothers, Inc. | See Footnotes 1, 2 and 3 | S - Sale | $3.12 | -179 | 161,278 | 0% | -$558 | ||||||
2020-07-01 | RLMD | Relmada Therapeutics, Inc. | Casamento Charles J | Dir | S - Sale | $43.89 | -3,000 | 58,484 | -5% | -$131,677 | ||||||
2020-07-01 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB,CEO,CFO, 10% | P - Purchase | $0.22 | +50 | 7,217,156 | 0% | +$11 | ||||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Sofinnova Venture Partners X, L.P. | 10% | P - Purchase | $17.00 | +58,823 | 1,515,073 | +4% | +$999,991 | |||||
| D | 2020-06-29 | PCRX | Pacira Biosciences, Inc. | Riker Lauren Bullaro | VP, Finance | S - Sale+OE | $49.47 | -6,000 | 12,633 | -32% | -$296,800 | |||||
| D | 2020-06-29 | PCRX | Pacira Biosciences, Inc. | Laranjeira Charles Anthony | SVP, Technical Operations | S - Sale+OE | $50.27 | -60,101 | 20,250 | -75% | -$3,021,314 | |||||
| DM | 2020-06-29 | MYOK | Myokardia, Inc. | Cranston Mary B | Dir | S - Sale+OE | $96.63 | -22,000 | 0 | -100% | -$2,125,966 | |||||
2020-07-01 | RAPT | Rapt Therapeutics, Inc. | Ho William | Chief Medical Officer | S - Sale | $28.61 | -1,000 | 71,858 | -1% | -$28,610 | ||||||
| DM | 2020-06-29 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $120.18 | -20,000 | 664,185 | -3% | -$2,403,689 | |||||
| D | 2020-06-29 | FOLD | Amicus Therapeutics, Inc. | Barth Jay | Chief Medical Officer | S - Sale+OE | $15.51 | -30,000 | 163,224 | -16% | -$465,195 | |||||
| M | 2020-06-29 | RAPT | Rapt Therapeutics, Inc. | Robbins Wendye | Dir | P - Purchase | $26.01 | +2,600 | 4,550 | +133% | +$67,632 | |||||
2020-06-29 | CTLT | Catalent, Inc. | Gunther Scott | SVP, Quality, Reg. Affairs | S - Sale | $72.00 | -2,824 | 13,365 | -17% | -$203,318 | ||||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Sonsini Peter W. | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Behbahani Ali | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | New Enterprise Associates 16, L.P. | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Walker Paul Edward | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Sandell Scott D | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Makower Joshua | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Makhzoumi Mohamad | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Florence Anthony A. Jr. | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Chang Carmen | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Baskett Forest | 10% | P - Purchase | $17.00 | +588,235 | 4,294,207 | +16% | +$9,999,995 | |||||
2020-06-29 | EVLO | Evelo Biosciences, Inc. | Flagship Ventures Fund IV General Partner LLC | 10% | P - Purchase | $3.75 | +4,666,666 | 17,614,323 | +36% | +$17,499,998 | ||||||
2020-06-29 | MGTA | Magenta Therapeutics, Inc. | Booth Bruce | Dir | P - Purchase | $8.00 | +1,250,000 | 5,367,125 | +30% | +$10,000,000 | ||||||
| M | 2020-06-29 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $191.85 | -5,251 | 63,039,584 | 0% | -$1,007,391 | |||||
| D | 2020-06-30 | FULC | Fulcrum Therapeutics, Inc. | Wallace Owen B. | Chief Scientific Officer | S - Sale+OE | $20.00 | -141 | 127,088 | 0% | -$2,820 | |||||
2020-06-29 | BGNE | Beigene, Ltd. | Liang Howard | CFO, Chief Strategy Officer | S - Sale | $191.23 | -300 | 168,415 | 0% | -$57,368 | ||||||
2020-06-29 | HOOK | Hookipa Pharma Inc. | Sofinnova Capital VI Fcpr | 10% | S - Sale | $11.78 | -3,280 | 3,960,574 | 0% | -$38,628 | ||||||
| D | 2020-06-30 | AKUS | Akouos, Inc. | Pivotal Bioventure Partners Fund I, L.P. | 10% | P - Purchase | $17.00 | +294,117 | 1,794,088 | +20% | +$4,999,989 | |||||
2020-06-29 | PTCT | Ptc Therapeutics, Inc. | Hill Emily Luisa | CFO | S - Sale | $52.50 | -2,581 | 13,610 | -16% | -$135,503 | ||||||
2020-06-30 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $163.21 | -166,832 | 111,560,304 | 0% | -$27,227,760 | ||||||
2020-06-26 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $163.01 | -31,737 | 111,738,567 | 0% | -$5,173,404 | ||||||
2020-06-26 | KIN | Kindred Biosciences, Inc. | Park West Asset Management LLC | 10% | S - Sale | $4.71 | -115,136 | 6,628,757 | -2% | -$542,291 | ||||||
2020-06-30 | TBIO | Translate Bio, Inc. | Shire Human Genetic Therapies, Inc. | 10% | S - Sale | $20.68 | -6,824,992 | 0 | -100% | -$141,140,835 | ||||||
| DM | 2020-06-26 | FBRX | Forte Biosciences, Inc. | Riley Antony A | CFO | P - Purchase | $14.39 | +6,700 | 36,065 | +23% | +$96,445 | |||||
2020-06-30 | VKTX | Viking Therapeutics, Inc. | Foehr Matthew W | Dir | S - Sale | $7.35 | -13,000 | 26,250 | -33% | -$95,550 | ||||||
2020-06-26 | RYTM | Rhythm Pharmaceuticals, Inc. | Foley Todd | Dir | S - Sale | $25.04 | -300 | 1,909,258 | 0% | -$7,512 | ||||||
| D | 2020-06-29 | KRTX | Karuna Therapeutics, Inc. | Paul Steven M | Pres,amp; CEO | S - Sale+OE | $103.50 | -292,207 | 106,485 | -73% | -$30,243,425 | |||||
| DM | 2020-06-26 | BGNE | Beigene, Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $195.73 | -4,014 | 326,247 | -1% | -$785,647 | |||||
2020-06-29 | REGN | Regeneron Pharmaceuticals, Inc. | Landry Robert E | EVP Finance CFO | S - Sale | $612.57 | -400 | 24,173 | -2% | -$245,029 | ||||||
2020-06-29 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $163.39 | -11,431 | 111,727,136 | 0% | -$1,867,760 | ||||||
2020-06-26 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $163.01 | -31,737 | 111,738,567 | 0% | -$5,173,404 | ||||||
2020-06-26 | BMRN | Biomarin Pharmaceutical Inc | Dere Willard H | Dir | S - Sale | $123.61 | -4,430 | 13,290 | -25% | -$547,592 | ||||||
| D | 2020-06-29 | UTHR | United Therapeutics Corp | Dwek Raymond | Dir | S - Sale+OE | $116.81 | -4,600 | 0 | -100% | -$537,323 | |||||
2020-06-26 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controller | S - Sale | $16.15 | -317 | 4,838 | -6% | -$5,120 | ||||||
2020-06-26 | EPZM | Epizyme, Inc. | Bazemore Robert B | Pres, CEO | S - Sale | $16.15 | -4,773 | 250,098 | -2% | -$77,084 | ||||||
2020-06-26 | EPZM | Epizyme, Inc. | Tombesi Paolo | CFO | S - Sale | $16.15 | -1,805 | 21,942 | -8% | -$29,151 | ||||||
2020-06-26 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Officer | S - Sale | $16.15 | -1,805 | 78,611 | -2% | -$29,151 | ||||||
2020-06-26 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | S - Sale | $16.15 | -2,728 | 57,507 | -5% | -$44,057 | ||||||
2020-06-29 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | P - Purchase | $78.50 | +650 | 408,798 | 0% | +$51,025 | ||||||
2020-06-29 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | CFO | P - Purchase | $76.64 | +777 | 41,277 | +2% | +$59,549 | ||||||
| D | 2020-06-25 | IONS | Ionis Pharmaceuticals Inc | Castleman Breaux | Dir | S - Sale+OE | $60.00 | -10,000 | 15,183 | -40% | -$600,000 | |||||
| D | 2020-06-25 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $59.77 | -15,000 | 32,364 | -32% | -$896,505 | |||||
2020-06-25 | RTRX | Retrophin, Inc. | Aselage Steve | Dir | S - Sale | $20.00 | -10,000 | 238,732 | -4% | -$200,000 | ||||||
2020-06-25 | FBRX | Forte Biosciences, Inc. | Wagner Paul A. | See Remarks, 10% | P - Purchase | $14.48 | +7,000 | 2,279,049 | 0% | +$101,356 | ||||||
2020-06-25 | BCEL | Atreca, Inc. | Serafini Tito | Chief Strategy Officer | S - Sale | $25.01 | -600 | 443,875 | 0% | -$15,008 | ||||||
2020-06-25 | BCEL | Atreca, Inc. | Robinson William Hewitt | Dir | S - Sale | $25.02 | -600 | 413,948 | 0% | -$15,010 | ||||||
| D | 2020-06-25 | CTLT | Catalent, Inc. | Gennadios Aristippos | Pres Softgel, Oral Tech | S - Sale+OE | $73.00 | -8,325 | 44,520 | -16% | -$607,725 | |||||
| M | 2020-06-25 | RYTM | Rhythm Pharmaceuticals, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $23.05 | -150,323 | 5,271,989 | -3% | -$3,465,615 | |||||
2020-06-25 | VSTM | Verastem, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $1.91 | -1,161,300 | 16,142,051 | -7% | -$2,219,941 | ||||||
2020-06-29 | REGN | Regeneron Pharmaceuticals, Inc. | Sing George L | Dir | S - Sale | $608.91 | -3,000 | 124,665 | -2% | -$1,826,721 | ||||||
| M | 2020-06-24 | IONS | Ionis Pharmaceuticals Inc | Crooke Stanley T | Exec COB | S - Sale | $59.67 | -14,914 | 702,412 | -2% | -$889,907 | |||||
2020-06-26 | EPZM | Epizyme, Inc. | Mott David M | Dir | P - Purchase | $16.03 | +62,019 | 189,560 | +49% | +$994,165 | ||||||
2020-06-25 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $38.81 | -100,000 | 2,605,237 | -4% | -$3,881,017 | ||||||
| D | 2020-06-25 | RAPT | Rapt Therapeutics, Inc. | Giordano Michael F | Dir | S - Sale+OE | $33.37 | -19,013 | 0 | -100% | -$634,464 | |||||
2020-06-25 | RAPT | Rapt Therapeutics, Inc. | Lam Karen C | VP, Finance, Controller | S - Sale | $35.00 | -875 | 12,735 | -6% | -$30,625 | ||||||
| DM | 2020-06-25 | UTHR | United Therapeutics Corp | Rothblatt Martine A | COB, CEO | S - Sale+OE | $123.03 | -20,000 | 664,185 | -3% | -$2,460,654 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |